Navigation Links
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Date:7/9/2008

Orexigen is the only company with two late-stage product candidates to

address a broad spectrum of obesity patients

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced today that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company's two late-stage obesity product candidates. The trial is designed to build on highly encouraging safety and efficacy results from a previous Phase IIb trial of Empatic, which demonstrated robust weight loss at 48 weeks ranging from approximately 11 percent to 15 percent in obese patients completing the trial and a discontinuation rate due to adverse events that was not significantly different than placebo.

"Initiation of ZB-202 is an important milestone for our Empatic program and the final anticipated step before moving into Phase III development," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "Empatic continues to be an important component of the Company's obesity program. Along with Contrave(R), now in Phase III clinical trials, these product candidates both have the potential to target a large, distinct and complementary segment within the obesity market."

Orexigen is the only company currently developing two late-stage product candidates to address the full spectrum of obesity ranging from mild-to-moderate and moderate-to-severe obesity. Obesity has become a national epidemic, with more than 70 million Americans classified as obese and 300,000 deaths a year attributable to obesity, according to the Centers for Disease Control (CDC). Obesity is associated with a number of significant medical conditions, including diabetes, hypertension, high cho
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
3. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
4. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
5. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
6. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
7. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
10. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
11. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... , the leader in heart rate monitoring and fitness assessment ... Rate Technology Supplier" for U.S. Soccer through 2013.  ... major national and international events, including the London 2012 Olympic ... be used to help these nine National Teams gain a ...
... Feb. 29, 2012  Four Rivers Software Systems, Inc. the ... to the healthcare industry, is pleased to announce ... part of this critical release, we have included ... that will benefit users.  The ...
Cached Medicine Technology:Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 2Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 3Four Rivers Software Systems Launches TMS 2012.5.5 2
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , , MONDAY, May 19 (HealthDay News) -- Findings from two ... erectile dysfunction can be a powerful early warning sign for ... men with diabetes but no signs of heart disease found ... percent more likely to have a heart attack or other ...
... of Nebraska Medical Center-led pilot study that showed antidepressants ... and neck cancer patients is the focus of an ... one of the publications produced by the Journal of ... led by UNMCs William Lydiatt, M.D., and Bill Burke, ...
... study from University Hospitals Case Medical Center (UHCMC) finds ... with malignant brain tumors are not treated as aggressively ... Furthermore, the researchers find that if patients over 75 ... and radiation, they have better survival rates. The findings ...
... have new life as a stroke treatment, researchers say. ... ways inhibiting white blood cells and enzymes that, ... vessels, respectively, says Dr. David Hess, chair of the ... School of Medicine. The broad-spectrum antibiotic also seems to ...
... May 19 Baker Energy, a unit,of Michael ... that the Wyoming,State Department of Environmental Quality (DEQ) ... (Huber), with a first-of-its-kind award,for their joint commitment ... http://www.newscom.com/cgi-bin/prnh/20061214/BAKERLOGO ), Wyoming DEQ Storm ...
... a nationwide clinical trial led by a University of ... ablation is an effective treatment for dysplasia in people ... deadly gastrointestinal cancer. , The interim results show there ... and a placebo or sham treatment, said Dr. Nicholas ...
Cached Medicine News:Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 2Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 2Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: